Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022
Influenza and Other Respiratory Viruses · 2023-03 · 17 (3)
DOI: 10.1111/irv.13104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2023-03. Verfasst von Joshua G Petrie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Marshfield Clinic Research Institute Marshfield Wisconsin USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centers for Disease Control and Prevention, Marshfield Clinic Research Institute, University of Wisconsin-Madison.
Abstract (Originalsprache)
Background
US recommendations for COVID‐19 vaccine boosters have expanded in terms of age groups covered and numbers of doses recommended, whereas evolution of Omicron sublineages raises questions about ongoing vaccine effectiveness.
Methods
We estimated effectiveness of monovalent COVID‐19 mRNA booster vaccination versus two‐dose primary series during a period of Omicron variant virus circulation in a community cohort with active illness surveillance. Hazard ratios comparing SARS‐CoV‐2 infection between booster versus primary series vaccinated individuals were estimated using Cox proportional hazards models with time‐varying booster status. Models were adjusted for age and prior SARS‐CoV‐2 infection. The effectiveness of a second booster among adults ≥50 years of age was similarly estimated.
Results
The analysis included 883 participants ranging in age, from 5 to >90 years. Relative effectiveness was 51% (95% CI: 34%, 64%) favoring the booster compared with primary series vaccination and did not vary by prior infection status. Relative effectiveness was 74% (95% CI: 57%, 84%) at 15 to 90 days after booster receipt, but declined to 42% (95% CI: 16%, 61%) after 91 to 180 days, and to 36% (95% CI: 3%, 58%) after 180 days. The relative effectiveness of a second booster compared to a single booster was 24% (95% CI: −40% to 61%).
Conclusions
An mRNA vaccine booster dose added significant protection against SARS‐CoV‐2 infection, but protection decreased over time. A second booster did not add significant protection for adults ≥50 years of age. Uptake of recommended bivalent boosters should be encouraged to increase protection against Omicron BA.4/BA.5 sublineages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marshfield Clinic Research Institute Marshfield Wisconsin USA.
- Influenza Division Centers for Disease Control and Prevention Atlanta Georgia USA.
- Department of Pathobiological Sciences, School of Veterinary Medicine University of Wisconsin- Madison Wisconsin USA.
ORCID-Profile: Joshua G Petrie, Jennifer P King, Melissa A Rolfes, Edward A Belongia
Förderung
- Centers for Disease Control and Prevention
- Marshfield Clinic Research Institute
- University of Wisconsin-Madison
Zitieren
APA
Petrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A., Meece, J. K., Pattinson, D., Neumann, G., Kawaoka, Y., Belongia, E. A., & McLean, H. Q. (2023). Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022. Influenza and Other Respiratory Viruses, 17(3). https://doi.org/10.1111/irv.13104
Vancouver
Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, et al. Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022. Influenza and Other Respiratory Viruses. 2023;17(3). doi:10.1111/irv.13104
BibTeX
@article{Petrie2023,
author = {Petrie, Joshua G and King, Jennifer P and McClure, David L and Rolfes, Melissa A and Meece, Jennifer K and Pattinson, David and Neumann, Gabriele and Kawaoka, Yoshihiro and Belongia, Edward A and McLean, Huong Q},
title = {Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022},
journal = {Influenza and Other Respiratory Viruses},
year = {2023},
volume = {17},
number = {3},
doi = {10.1111/irv.13104}
}
EUVIMED